Recent Update of Renin-angiotensin-aldosterone System in the Pathogenesis of Hypertension
Open Access
- 1 January 2013
- journal article
- review article
- Published by The Korean Society of Electrolyte Metabolism in Electrolytes & Blood Pressure
- Vol. 11 (2), 41-45
- https://doi.org/10.5049/ebp.2013.11.2.41
Abstract
The activation of renin-angiotensin-aldosterine system(RAAS) is one of the main pathogenesis of hypertension. All the components of RAAS are present in the kidneys at higher concentrations compared to plasma levels, and intrarenal formation of angiotensin II (Ang II) is independent of the systemic RAAS. There are some unique features in intrarenal RAAS compared to systemic RAAS. Unlike JG cells where Ang II inhibits renin release via the AngII type 1 (AT1) receptor by negative feedback, in the collecting duct Ang II stimulates renin expression via the AT1 receptor. Upregulated renin produced in the distal nephron may be able to support continued intrarenal Ang II formation leading to amplification or maintenance of the hypertensive state.The recently discovered angiotensin-converting enzyme-related carboxypeptidase 2 (ACE2)-Angiotensin-(1-7) Ang-(1-7)-Mas receptor axis has an opposing function to that of the ACE-Ang II-AT1 receptor axis.The ACE2 deficiency was associated with an increase in blood pressure, and ACE2 knockout mice have highlighted hypertensive response to Ang II infusion associated with exaggerated accumulation of Ang II in the kidney. Recently, several numbers of patients have been evaluated as the activators of ACE2-Ang-(1-7)-Mas receptor axis, which can be divided into two main classes: aimed to increase the activity of ACE2, and directed to stimulate the Ang-(1-7) receptor Mas. In order to investigate new targets for hypertension and kidney disease, further research on the function of the ACE-Ang-(1-7)-Mas receptor axis is required.Keywords
This publication has 23 references indexed in Scilit:
- Intrarenal angiotensin II and its contribution to the genesis of chronic hypertensionCurrent Opinion in Pharmacology, 2011
- A redox switch in angiotensinogen modulates angiotensin releaseNature, 2010
- Human Recombinant ACE2 Reduces the Progression of Diabetic NephropathyDiabetes, 2009
- Angiotensin-(1–7) and the G Protein-Coupled Receptor Mas Are Key Players in Renal InflammationPLOS ONE, 2009
- Discovery and Validation of Novel Peptide Agonists for G-protein-coupled ReceptorsOnline Journal of Public Health Informatics, 2008
- Transgenic Angiotensin-Converting Enzyme 2 Overexpression in Vessels of SHRSP Rats Reduces Blood Pressure and Improves Endothelial FunctionHypertension, 2008
- Structure-Based Identification of Small-Molecule Angiotensin-Converting Enzyme 2 Activators as Novel Antihypertensive AgentsHypertension, 2008
- The Intrarenal Renin-Angiotensin System: From Physiology to the Pathobiology of Hypertension and Kidney DiseasePharmacological Reviews, 2007
- Characterization of Renal Angiotensin-Converting Enzyme 2 in Diabetic NephropathyHypertension, 2003
- AVE 0991, a Nonpeptide Mimic of the Effects of Angiotensin-(1–7) on the EndotheliumHypertension, 2002